NCT00910676

Study About Preventive Treatment of Folliculitis Induced by Epidermal Growth Factor Receptor Inhibitors

Phase II Multicentric Study About Preventive Treatment of Folliculitis Induced by the EGF-R Inhibitors in Patients With Metastatic Colorectal Cancer and Treated by Cetuximab or With Non-small-cell Lung Carcinoma Treated by Erlotinib

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 30 (actual)
• Sponsor: Centre Oscar Lambret · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Patients will receive local prophylactic treatment (Diprosone cream) during 8 weeks from the beginning of the EGF-R inhibitors treatment, on the areas of the body susceptible to be affected by folliculitis.

Conditions

• Metastatic Colorectal Cancer
• Non-Small-Cell Lung Carcinoma

Interventions

Type	Name	Description
DRUG	Diprosone	* Start of treatment: as soon as the EGF-R inhibitors treatment begins * Application: On the body area susceptible to be affected by folliculitis, once a day, in the evening * Dosage: Quantity corresponded to around 2 tubes of 30 grams a week on the face, the chest and upper side of the back. There is no maximum dosage. * Period of treatment: 8 weeks

Timeline

• Start date: 2007-10-01
• Primary completion: 2009-03-01
• Completion: 2009-03-01
• First posted: 2009-06-01
• Last updated: 2012-07-31

Locations

3 sites across 1 country: France